FDA approves Eli Lilly’s Trulicity for type 2 diabetic patients

USFDA approves Eli Lilly's Trulicity to reduce cardiovascular risks in type 2 diabetic patients

538
Approved
Picture: Pixabay

USFDA approves Eli Lilly’s Trulicity to reduce cardiovascular risks in type 2 diabetic patients

(Reuters) Eli Lilly and Co said on the U.S. Food and Drug Administration (USFDA) has approved Trulicity for reducing cardiovascular risk factors in type 2 diabetic patients.

The approval makes Trulicity the first and only type 2 diabetes drug approved to reduce heart related risks in adults with and without established cardiovascular disease, the company said in a statement.

Also read: Zydus gets USFDA approval for generic Canasa